Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non- randomised, phase 1b/2 study  Jehan Dupuis, MD, Prof Franck Morschhauser, MD, Hervé Ghesquières, MD, Prof Hervé Tilly, MD, Prof Olivier Casasnovas, MD, Prof Catherine Thieblemont, MD, Vincent Ribrag, MD, Céline Bossard, MD, Fabien Le Bras, MD, Emmanuel Bachy, MD, Bénédicte Hivert, MD, Emmanuelle Nicolas-Virelizier, MD, Prof Fabrice Jardin, MD, Jean-Noel Bastie, MD, Sandy Amorim, MD, Julien Lazarovici, MD, Prof Antoine Martin, MD, Prof Bertrand Coiffier, MD  The Lancet Haematology  Volume 2, Issue 4, Pages e160-e165 (April 2015) DOI: 10.1016/S2352-3026(15)00023-X Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure Kaplan-Meier estimates of progression-free survival and overall survival Progression-free survival (A) and overall survival (B) for the whole efficacy population. Progression-free survival (C) and overall survival (D) for the population of patients treated at the recommended dose of 12 mg/m2 of romidepsin. Crosses show censoring events and shaded regions show 95% CIs. The Lancet Haematology 2015 2, e160-e165DOI: (10.1016/S2352-3026(15)00023-X) Copyright © 2015 Elsevier Ltd Terms and Conditions